25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ACIU (AC Immune Ltd) Stock Analysis
Buy, Hold or Sell?

Let's analyze AC Immune Ltd together

I guess you are interested in AC Immune Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – AC Immune Ltd’s Financial Insights
  • 📈 Technical Analysis (TA) – AC Immune Ltd’s Price Targets

I'm going to help you getting a better view of AC Immune Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about AC Immune Ltd

I send you an email if I find something interesting about AC Immune Ltd.

1. Quick Overview

1.1. Quick analysis of AC Immune Ltd (30 sec.)










1.2. What can you expect buying and holding a share of AC Immune Ltd? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
2.5%

What is your share worth?

Current worth
$1.15
Expected worth in 1 year
$0.55
How sure are you?
32.5%

+ What do you gain per year?

Total Gains per Share
$-0.61
Return On Investment
-32.3%

For what price can you sell your share?

Current Price per Share
$1.88
Expected price per share
$1.78 - $2.25
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of AC Immune Ltd (5 min.)




Live pricePrice per Share (EOD)
$1.88
Intrinsic Value Per Share
$-8.74 - $0.78
Total Value Per Share
$-7.59 - $1.93

2.2. Growth of AC Immune Ltd (5 min.)




Is AC Immune Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$115.9m$174.3m-$33.5m-23.8%

How much money is AC Immune Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$15.9m-$16.6m$764k4.8%
Net Profit Margin-1,650.7%-658.0%--

How much money comes from the company's main activities?

2.3. Financial Health of AC Immune Ltd (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#327 / 887

Most Revenue
#302 / 887

Most Profit
#615 / 887

Most Efficient
#749 / 887
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of AC Immune Ltd?

Welcome investor! AC Immune Ltd's management wants to use your money to grow the business. In return you get a share of AC Immune Ltd.

First you should know what it really means to hold a share of AC Immune Ltd. And how you can make/lose money.

Speculation

The Price per Share of AC Immune Ltd is $1.88. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of AC Immune Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in AC Immune Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.15. Based on the TTM, the Book Value Change Per Share is $-0.15 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.03 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of AC Immune Ltd.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.23-12.3%-0.16-8.4%-0.17-8.8%-0.18-9.5%-0.20-10.4%-0.10-5.3%
Usd Book Value Change Per Share-0.21-11.0%-0.15-8.1%-0.03-1.3%-0.12-6.4%-0.10-5.5%0.021.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.21-11.0%-0.15-8.1%-0.03-1.3%-0.12-6.4%-0.10-5.5%0.021.1%
Usd Price Per Share1.87-3.09-3.44-3.10-4.26-5.65-
Price to Earnings Ratio-2.02-1.26--8.13--3.43--4.81--37.30-
Price-to-Total Gains Ratio-9.05-3.37--9.61--7.62--17.72--25.48-
Price to Book Ratio1.62-2.16-1.96-1.80-2.01-3.00-
Price-to-Total Gains Ratio-9.05-3.37--9.61--7.62--17.72--25.48-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.88
Number of shares531
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.15-0.10
Usd Total Gains Per Share-0.15-0.10
Gains per Quarter (531 shares)-80.66-55.23
Gains per Year (531 shares)-322.62-220.92
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-323-3330-221-231
20-645-6560-442-452
30-968-9790-663-673
40-1290-13020-884-894
50-1613-16250-1105-1115
60-1936-19480-1326-1336
70-2258-22710-1547-1557
80-2581-25940-1768-1778
90-2904-29170-1988-1999
100-3226-32400-2209-2220

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%8.032.00.020.0%9.036.00.020.0%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%3.017.00.015.0%13.027.00.032.5%14.027.04.031.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%1.00.019.05.0%1.00.039.02.5%1.00.044.02.2%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%3.017.00.015.0%13.027.00.032.5%14.027.04.031.1%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of AC Immune Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.207-0.152-27%-0.025-88%-0.121-41%-0.104-50%0.021-1085%
Book Value Per Share--1.1551.399-17%1.737-34%1.771-35%2.111-45%1.968-41%
Current Ratio--1.5331.723-11%8.312-82%7.151-79%10.837-86%13.049-88%
Debt To Asset Ratio--0.5510.503+10%0.121+354%0.235+134%0.181+205%0.142+289%
Debt To Equity Ratio--1.2271.021+20%0.138+787%0.416+195%0.293+318%0.205+498%
Dividend Per Share----0%-0%-0%0.000-100%0.000-100%
Enterprise Value--223637290.000365833500.780-39%437814320.000-49%408065058.010-45%578938645.256-61%823728350.775-73%
Eps---0.232-0.158-32%-0.166-28%-0.178-23%-0.196-16%-0.099-57%
Ev To Ebitda Ratio---2.4900.841-396%-10.953+340%-5.125+106%-6.994+181%-9.614+286%
Ev To Sales Ratio--46.17762.584-26%63.328-27%8585.360-99%6285.717-99%2737.833-98%
Free Cash Flow Per Share---0.2340.138-269%-0.132-43%-0.067-71%-0.128-45%-0.067-71%
Free Cash Flow To Equity Per Share---0.2370.136-274%-0.002-99%-0.025-89%-0.078-67%0.039-710%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--0.779----------
Intrinsic Value_10Y_min---8.743----------
Intrinsic Value_1Y_max---0.217----------
Intrinsic Value_1Y_min---0.374----------
Intrinsic Value_3Y_max---0.427----------
Intrinsic Value_3Y_min---1.566----------
Intrinsic Value_5Y_max---0.366----------
Intrinsic Value_5Y_min---3.232----------
Market Cap188770800.000+1%187766700.000310492139.280-40%345535912.500-46%311973642.260-40%428067775.356-56%567150755.178-67%
Net Profit Margin---19.221-16.507-14%-6.580-66%-1570.399+8070%-944.733+4815%-475.517+2374%
Operating Margin---19.167-16.474-14%-7.154-63%-1578.160+8134%-949.384+4853%-477.846+2393%
Operating Ratio--20.56623.778-14%13.378+54%2832.559-99%1704.204-99%858.429-98%
Pb Ratio1.628+1%1.6202.163-25%1.960-17%1.797-10%2.013-20%2.995-46%
Pe Ratio-2.028-1%-2.0171.256-261%-8.125+303%-3.428+70%-4.814+139%-37.299+1749%
Price Per Share1.880+1%1.8703.085-39%3.441-46%3.105-40%4.262-56%5.648-67%
Price To Free Cash Flow Ratio-2.012-1%-2.0010.800-350%15.890-113%4.424-145%-0.203-90%-2.998+50%
Price To Total Gains Ratio-9.094-1%-9.0463.369-369%-9.611+6%-7.617-16%-17.719+96%-25.481+182%
Quick Ratio--2.7632.937-6%11.359-76%10.678-74%15.452-82%15.819-83%
Return On Assets---0.090-0.058-36%-0.087-4%-0.078-13%-0.078-14%-0.037-59%
Return On Equity---0.201-0.121-40%-0.099-51%-0.106-47%-0.098-51%-0.045-78%
Total Gains Per Share---0.207-0.152-27%-0.025-88%-0.121-41%-0.104-50%0.021-1085%
Usd Book Value--115937954.000140846183.500-18%174374117.000-34%177922651.500-35%212030164.700-45%197683579.750-41%
Usd Book Value Change Per Share---0.207-0.152-27%-0.025-88%-0.121-41%-0.104-50%0.021-1085%
Usd Book Value Per Share--1.1551.399-17%1.737-34%1.771-35%2.111-45%1.968-41%
Usd Dividend Per Share----0%-0%-0%0.000-100%0.000-100%
Usd Enterprise Value--223637290.000365833500.780-39%437814320.000-49%408065058.010-45%578938645.256-61%823728350.775-73%
Usd Eps---0.232-0.158-32%-0.166-28%-0.178-23%-0.196-16%-0.099-57%
Usd Free Cash Flow---23454694.00013854449.750-269%-13279639.750-43%-6751469.583-71%-12815572.400-45%-6695710.975-71%
Usd Free Cash Flow Per Share---0.2340.138-269%-0.132-43%-0.067-71%-0.128-45%-0.067-71%
Usd Free Cash Flow To Equity Per Share---0.2370.136-274%-0.002-99%-0.025-89%-0.078-67%0.039-710%
Usd Market Cap188770800.000+1%187766700.000310492139.280-40%345535912.500-46%311973642.260-40%428067775.356-56%567150755.178-67%
Usd Price Per Share1.880+1%1.8703.085-39%3.441-46%3.105-40%4.262-56%5.648-67%
Usd Profit---23272467.000-15924377.250-32%-16688446.500-28%-17946098.167-23%-19700267.450-15%-10571856.600-55%
Usd Revenue--1210770.0008652419.250-86%4735456.000-74%4863667.167-75%3122747.050-61%8072442.075-85%
Usd Total Gains Per Share---0.207-0.152-27%-0.025-88%-0.121-41%-0.104-50%0.021-1085%
 EOD+5 -3MRQTTM+5 -32YOY+5 -323Y+7 -305Y+8 -3110Y+7 -32

3.3 Fundamental Score

Let's check the fundamental score of AC Immune Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.028
Price to Book Ratio (EOD)Between0-11.628
Net Profit Margin (MRQ)Greater than0-19.221
Operating Margin (MRQ)Greater than0-19.167
Quick Ratio (MRQ)Greater than12.763
Current Ratio (MRQ)Greater than11.533
Debt to Asset Ratio (MRQ)Less than10.551
Debt to Equity Ratio (MRQ)Less than11.227
Return on Equity (MRQ)Greater than0.15-0.201
Return on Assets (MRQ)Greater than0.05-0.090
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of AC Immune Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.742
Ma 20Greater thanMa 501.853
Ma 50Greater thanMa 1001.710
Ma 100Greater thanMa 2002.029
OpenGreater thanClose1.960
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About AC Immune Ltd

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Fundamental data was last updated by Penke on 2025-06-18 22:17:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is cheap.
Based on how much money comes from the company's main activities, the company is cheap.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit AC Immune Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare AC Immune Ltd to the Biotechnology industry mean.
  • A Net Profit Margin of -1,922.1% means that $-19.22 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of AC Immune Ltd:

  • The MRQ is -1,922.1%. The company is making a huge loss. -2
  • The TTM is -1,650.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,922.1%TTM-1,650.7%-271.4%
TTM-1,650.7%YOY-658.0%-992.7%
TTM-1,650.7%5Y-94,473.3%+92,822.6%
5Y-94,473.3%10Y-47,551.7%-46,921.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,922.1%-91.7%-1,830.4%
TTM-1,650.7%-142.9%-1,507.8%
YOY-658.0%-187.4%-470.6%
3Y-157,039.9%-248.5%-156,791.4%
5Y-94,473.3%-344.1%-94,129.2%
10Y-47,551.7%-478.1%-47,073.6%
4.3.1.2. Return on Assets

Shows how efficient AC Immune Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare AC Immune Ltd to the Biotechnology industry mean.
  • -9.0% Return on Assets means that AC Immune Ltd generated $-0.09 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of AC Immune Ltd:

  • The MRQ is -9.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -5.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.0%TTM-5.8%-3.2%
TTM-5.8%YOY-8.7%+2.9%
TTM-5.8%5Y-7.8%+2.0%
5Y-7.8%10Y-3.7%-4.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.0%-11.3%+2.3%
TTM-5.8%-11.2%+5.4%
YOY-8.7%-11.0%+2.3%
3Y-7.8%-11.6%+3.8%
5Y-7.8%-11.8%+4.0%
10Y-3.7%-13.6%+9.9%
4.3.1.3. Return on Equity

Shows how efficient AC Immune Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare AC Immune Ltd to the Biotechnology industry mean.
  • -20.1% Return on Equity means AC Immune Ltd generated $-0.20 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of AC Immune Ltd:

  • The MRQ is -20.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -12.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-20.1%TTM-12.1%-8.0%
TTM-12.1%YOY-9.9%-2.2%
TTM-12.1%5Y-9.8%-2.3%
5Y-9.8%10Y-4.5%-5.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-20.1%-13.0%-7.1%
TTM-12.1%-14.2%+2.1%
YOY-9.9%-14.2%+4.3%
3Y-10.6%-16.7%+6.1%
5Y-9.8%-17.3%+7.5%
10Y-4.5%-19.4%+14.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of AC Immune Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient AC Immune Ltd is operating .

  • Measures how much profit AC Immune Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare AC Immune Ltd to the Biotechnology industry mean.
  • An Operating Margin of -1,916.7% means the company generated $-19.17  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of AC Immune Ltd:

  • The MRQ is -1,916.7%. The company is operating very inefficient. -2
  • The TTM is -1,647.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-1,916.7%TTM-1,647.4%-269.3%
TTM-1,647.4%YOY-715.4%-932.0%
TTM-1,647.4%5Y-94,938.4%+93,291.1%
5Y-94,938.4%10Y-47,784.6%-47,153.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,916.7%-228.1%-1,688.6%
TTM-1,647.4%-264.3%-1,383.1%
YOY-715.4%-205.1%-510.3%
3Y-157,816.0%-216.3%-157,599.7%
5Y-94,938.4%-346.1%-94,592.3%
10Y-47,784.6%-450.5%-47,334.1%
4.3.2.2. Operating Ratio

Measures how efficient AC Immune Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 20.57 means that the operating costs are $20.57 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of AC Immune Ltd:

  • The MRQ is 20.566. The company is inefficient in keeping operating costs low. -1
  • The TTM is 23.778. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ20.566TTM23.778-3.212
TTM23.778YOY13.378+10.400
TTM23.7785Y1,704.204-1,680.426
5Y1,704.20410Y858.429+845.775
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ20.5662.076+18.490
TTM23.7782.760+21.018
YOY13.3783.043+10.335
3Y2,832.5593.523+2,829.036
5Y1,704.2044.724+1,699.480
10Y858.4296.380+852.049
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of AC Immune Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if AC Immune Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.53 means the company has $1.53 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of AC Immune Ltd:

  • The MRQ is 1.533. The company is able to pay all its short-term debts. +1
  • The TTM is 1.723. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.533TTM1.723-0.190
TTM1.723YOY8.312-6.589
TTM1.7235Y10.837-9.114
5Y10.83710Y13.049-2.212
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5333.674-2.141
TTM1.7233.745-2.022
YOY8.3124.121+4.191
3Y7.1514.643+2.508
5Y10.8375.733+5.104
10Y13.0496.146+6.903
4.4.3.2. Quick Ratio

Measures if AC Immune Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare AC Immune Ltd to the Biotechnology industry mean.
  • A Quick Ratio of 2.76 means the company can pay off $2.76 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of AC Immune Ltd:

  • The MRQ is 2.763. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.937. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.763TTM2.937-0.174
TTM2.937YOY11.359-8.422
TTM2.9375Y15.452-12.515
5Y15.45210Y15.819-0.367
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.7632.941-0.178
TTM2.9373.182-0.245
YOY11.3593.794+7.565
3Y10.6784.363+6.315
5Y15.4525.707+9.745
10Y15.8196.474+9.345
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of AC Immune Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of AC Immune Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare AC Immune Ltd to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.55 means that AC Immune Ltd assets are financed with 55.1% credit (debt) and the remaining percentage (100% - 55.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of AC Immune Ltd:

  • The MRQ is 0.551. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.503. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.551TTM0.503+0.048
TTM0.503YOY0.121+0.382
TTM0.5035Y0.181+0.322
5Y0.18110Y0.142+0.039
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5510.324+0.227
TTM0.5030.356+0.147
YOY0.1210.336-0.215
3Y0.2350.340-0.105
5Y0.1810.350-0.169
10Y0.1420.383-0.241
4.5.4.2. Debt to Equity Ratio

Measures if AC Immune Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare AC Immune Ltd to the Biotechnology industry mean.
  • A Debt to Equity ratio of 122.7% means that company has $1.23 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of AC Immune Ltd:

  • The MRQ is 1.227. The company is able to pay all its debts with equity. +1
  • The TTM is 1.021. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.227TTM1.021+0.206
TTM1.021YOY0.138+0.883
TTM1.0215Y0.293+0.728
5Y0.29310Y0.205+0.088
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2270.384+0.843
TTM1.0210.437+0.584
YOY0.1380.413-0.275
3Y0.4160.452-0.036
5Y0.2930.464-0.171
10Y0.2050.511-0.306
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings AC Immune Ltd generates.

  • Above 15 is considered overpriced but always compare AC Immune Ltd to the Biotechnology industry mean.
  • A PE ratio of -2.02 means the investor is paying $-2.02 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of AC Immune Ltd:

  • The EOD is -2.028. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.017. Based on the earnings, the company is expensive. -2
  • The TTM is 1.256. Based on the earnings, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-2.028MRQ-2.017-0.011
MRQ-2.017TTM1.256-3.273
TTM1.256YOY-8.125+9.381
TTM1.2565Y-4.814+6.070
5Y-4.81410Y-37.299+32.485
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.028-2.123+0.095
MRQ-2.017-2.045+0.028
TTM1.256-2.564+3.820
YOY-8.125-3.655-4.470
3Y-3.428-3.716+0.288
5Y-4.814-6.080+1.266
10Y-37.299-6.645-30.654
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of AC Immune Ltd:

  • The EOD is -2.012. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.001. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 0.800. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-2.012MRQ-2.001-0.011
MRQ-2.001TTM0.800-2.802
TTM0.800YOY15.890-15.090
TTM0.8005Y-0.203+1.003
5Y-0.20310Y-2.998+2.795
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.012-2.989+0.977
MRQ-2.001-2.726+0.725
TTM0.800-3.819+4.619
YOY15.890-4.278+20.168
3Y4.424-5.103+9.527
5Y-0.203-8.510+8.307
10Y-2.998-9.228+6.230
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of AC Immune Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.62 means the investor is paying $1.62 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of AC Immune Ltd:

  • The EOD is 1.628. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.620. Based on the equity, the company is underpriced. +1
  • The TTM is 2.163. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.628MRQ1.620+0.009
MRQ1.620TTM2.163-0.543
TTM2.163YOY1.960+0.203
TTM2.1635Y2.013+0.150
5Y2.01310Y2.995-0.982
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.6281.878-0.250
MRQ1.6201.856-0.236
TTM2.1632.144+0.019
YOY1.9602.465-0.505
3Y1.7972.557-0.760
5Y2.0133.665-1.652
10Y2.9954.340-1.345
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of AC Immune Ltd.

4.8.1. Institutions holding AC Immune Ltd

Institutions are holding 26.121% of the shares of AC Immune Ltd.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Bvf Inc19.74141.5108198224363000001.5367
2025-03-31BlackRock Inc1.15190.00011156591-1055931-47.7252
2024-12-31Wells Fargo & Co0.99160.0006995636-112402-10.1442
2025-03-31Renaissance Technologies Corp0.80020.0023803469632718.5478
2025-03-31Junked Platinum Investment Management Ltd0.73630.0801739342-212727-22.3437
2025-03-31Northern Trust Corp0.37550.0001377086-25945-6.4375
2025-03-31Acadian Asset Management LLC0.36970.00193711773711770
2025-03-31Deutsche Bank AG0.25230.000225337500
2025-03-31Dimensional Fund Advisors, Inc.0.23660.000123755810614880.7762
2025-03-31Millennium Management LLC0.21190.00022127509371078.7214
2025-03-31Marshall Wace Asset Management Ltd0.21130.0005212184145866219.9493
2025-03-31Citadel Advisors Llc0.15080.00011514611435981826.2495
2025-03-31Handelsbanken Fonder AB0.12950.001130000-20000-13.3333
2025-03-31Eversept Partners, LLC0.10030.01911007521007520
2025-03-31Morgan Stanley - Brokerage Accounts0.0717072004-94551-56.7686
2025-03-31Geode Capital Management, LLC0.063806409000
2024-12-31UBS Group AG0.049504967835050239.609
2025-03-31Banque Cantonale Vaudoise0.02660.002226712815043.9069
2025-03-31SEI Investments Co0.02480.000124897248970
2025-03-31Two Sigma Advisers, LLC0.02350.0001236101020076.0626
Total 25.71921.619525824808-118737-0.5%

4.9.2. Funds holding AC Immune Ltd

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-05-31iShares Biotechnology ETF0.35360.012235502200
2025-03-31BlackRock Health Sciences Term Trust0.25770.0335258714-370115-58.8578
2025-04-30DWS ESG Biotech LC0.25240.1317253388-4-0.0016
2025-04-30Monega ARIAD Innovation R0.12950.226113000000
2025-04-30BlackRock Health Sciences Opps Inv A0.11540.0029115866-242435-67.6624
2025-05-31Handelsbanken Europa Småbolag (A1 SEK)0.10460.087105000-20000-16
2025-04-30Fidelity Nasdaq Composite Index0.06310.000763341-749-1.1687
2024-12-31BlackRock Health Sciences0.06260.031162903-15277-19.5408
2025-05-31iShares Nasdaq US Biotech ETF USD Acc0.04650.01874664900
2025-04-30DFA US Targeted Value I0.02970.00042985000
2025-04-30Top Class Healthcare FI0.02690.3792700000
2024-12-31China Universal NASDAQ Bio-Tch ETF(QDII)0.02090.026720970934980.4492
2025-03-04Acadian All Ctry Wld ex US SCap Eq CL A0.01580.01691588400
2025-04-30DFA US Vector Equity I0.01580.00061582100
2025-05-30Dimensional US Targeted Value ETF0.01570.00031579700
2025-04-30DFA US Small Cap I0.01480.00021486800
2025-05-30Dimensional US Core Equity 2 ETF0.01340.00011346800
2025-04-30Dimensional Global Small Coms USD Acc0.01220.001512203-12-0.0982
2025-04-30Dimensional World Equity GBP Acc0.01190.000411973-3-0.0251
2025-04-30DFA US Core Equity 2 I0.01180.00011181200
Total 1.57430.97011580529-639246-40.4%
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in CHF. All numbers in thousands.

Summary
Total Assets211,082
Total Liabilities116,284
Total Stockholder Equity94,798
 As reported
Total Liabilities 116,284
Total Stockholder Equity+ 94,798
Total Assets = 211,082

Assets

Total Assets211,082
Total Current Assets152,134
Long-term Assets58,948
Total Current Assets
Cash And Cash Equivalents 19,960
Short-term Investments 125,654
Net Receivables 2,913
Other Current Assets 3,607
Total Current Assets  (as reported)152,134
Total Current Assets  (calculated)152,134
+/-0
Long-term Assets
Property Plant Equipment 7,947
Long Term Investments 585
Intangible Assets 50,416
Long-term Assets  (as reported)58,948
Long-term Assets  (calculated)58,948
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities99,246
Long-term Liabilities17,038
Total Stockholder Equity94,798
Total Current Liabilities
Short-term Debt 1,033
Accounts payable 2,391
Other Current Liabilities 11,146
Total Current Liabilities  (as reported)99,246
Total Current Liabilities  (calculated)14,570
+/- 84,676
Long-term Liabilities
Capital Lease Obligations 5,175
Long-term Liabilities  (as reported)17,038
Long-term Liabilities  (calculated)5,175
+/- 11,863
Total Stockholder Equity
Common Stock2,230
Retained Earnings -386,212
Accumulated Other Comprehensive Income -1
Other Stockholders Equity 478,781
Total Stockholder Equity (as reported)94,798
Total Stockholder Equity (calculated)94,798
+/-0
Other
Capital Stock2,230
Cash and Short Term Investments 145,614
Common Stock Shares Outstanding 100,409
Current Deferred Revenue84,676
Liabilities and Stockholders Equity 211,082
Net Debt -14,785
Net Invested Capital 94,798
Net Working Capital 52,888
Property Plant and Equipment Gross 20,776
Short Long Term Debt Total 5,175



5.2. Balance Sheets Structured

Currency in CHF. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-31
> Total Assets 
0
0
0
30,296
0
34,976
55,139
79,931
73,545
103,282
160,683
156,100
144,599
131,288
125,441
132,013
120,014
112,556
208,724
196,556
312,892
296,222
315,349
299,250
288,232
273,258
256,610
238,740
227,959
211,090
203,396
261,443
235,519
216,786
205,557
185,938
169,150
156,228
142,986
182,814
167,281
237,535
244,248
230,913
211,082
211,082230,913244,248237,535167,281182,814142,986156,228169,150185,938205,557216,786235,519261,443203,396211,090227,959238,740256,610273,258288,232299,250315,349296,222312,892196,556208,724112,556120,014132,013125,441131,288144,599156,100160,683103,28273,54579,93155,13934,976030,296000
   > Total Current Assets 
0
0
0
29,667
3,306
34,371
54,486
79,346
72,813
102,529
159,683
154,894
142,389
128,759
122,781
129,534
116,450
108,881
205,197
192,928
306,936
290,346
309,450
292,774
282,020
267,144
250,589
231,767
220,489
202,802
195,376
202,634
177,058
158,380
147,602
128,094
111,688
99,152
86,179
125,153
109,873
180,543
187,590
171,994
152,134
152,134171,994187,590180,543109,873125,15386,17999,152111,688128,094147,602158,380177,058202,634195,376202,802220,489231,767250,589267,144282,020292,774309,450290,346306,936192,928205,197108,881116,450129,534122,781128,759142,389154,894159,683102,52972,81379,34654,48634,3713,30629,667000
       Cash And Cash Equivalents 
0
0
0
3,306
-3,306
19,355
53,685
76,522
67,860
82,377
157,592
152,210
138,084
124,180
117,210
124,377
109,669
102,664
199,122
156,462
222,138
205,735
212,457
193,587
182,860
177,464
176,567
160,893
151,092
104,135
93,584
82,216
57,835
63,147
44,503
31,586
57,434
40,007
31,927
78,494
57,009
51,564
32,417
36,275
19,960
19,96036,27532,41751,56457,00978,49431,92740,00757,43431,58644,50363,14757,83582,21693,584104,135151,092160,893176,567177,464182,860193,587212,457205,735222,138156,462199,122102,664109,669124,377117,210124,180138,084152,210157,59282,37767,86076,52253,68519,355-3,3063,306000
       Short-term Investments 
0
0
0
0
6,612
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,000
80,000
80,000
90,000
95,000
95,000
85,000
70,000
65,000
65,000
95,000
95,000
116,000
116,000
91,000
96,000
91,000
48,000
53,000
48,000
24,554
47,812
123,560
125,478
129,214
125,654
125,654129,214125,478123,56047,81224,55448,00053,00048,00091,00096,00091,000116,000116,00095,00095,00065,00065,00070,00085,00095,00095,00090,00080,00080,00030,000000000000000006,6120000
       Net Receivables 
0
0
0
53
0
63
54
316
1,762
15,880
1,259
1,406
2,022
2,615
3,587
3,717
4,243
2,631
3,390
4,102
1,798
547
939
1,095
190
424
944
1,591
688
659
92
975
152
433
50
800
218
675
312
15,046
267
402
26,249
2,203
2,913
2,9132,20326,24940226715,04631267521880050433152975926596881,5919444241901,0959395471,7984,1023,3902,6314,2433,7173,5872,6152,0221,4061,25915,8801,7623165463053000
       Other Current Assets 
0
0
0
26,308
0
14,953
747
2,777
3,191
4,272
832
1,278
2,283
1,964
1,984
1,440
2,538
3,173
2,685
2,364
3,000
2,917
2,997
2,788
3,419
3,689
2,764
3,954
3,330
2,726
6,700
3,015
2,805
3,465
2,888
4,708
5,438
5,167
5,534
6,437
3,917
3,864
3,446
4,302
3,607
3,6074,3023,4463,8643,9176,4375,5345,1675,4384,7082,8883,4652,8053,0156,7002,7263,3303,9542,7643,6893,4192,7882,9972,9173,0002,3642,6853,1732,5381,4401,9841,9642,2831,2788324,2723,1912,77774714,953026,308000
   > Long-term Assets 
0
0
0
629
-3,306
605
653
585
732
753
1,000
1,206
2,210
2,529
2,660
2,479
3,564
3,675
3,527
3,628
5,956
5,876
5,899
6,476
6,212
6,114
6,021
6,973
7,470
8,288
8,020
58,809
58,461
58,406
57,955
57,844
57,462
57,076
56,807
57,661
57,408
56,992
56,658
58,919
58,948
58,94858,91956,65856,99257,40857,66156,80757,07657,46257,84457,95558,40658,46158,8098,0208,2887,4706,9736,0216,1146,2126,4765,8995,8765,9563,6283,5273,6753,5642,4792,6602,5292,2101,2061,000753732585653605-3,306629000
       Property Plant Equipment 
0
0
0
544
0
520
568
500
647
668
915
1,120
2,084
2,403
2,534
2,353
3,354
3,465
3,317
3,324
5,652
5,572
5,595
6,172
5,908
5,810
5,717
6,639
7,043
7,864
7,626
8,030
7,682
7,629
7,178
7,067
6,685
6,299
6,030
6,884
6,577
6,161
5,827
8,088
7,947
7,9478,0885,8276,1616,5776,8846,0306,2996,6857,0677,1787,6297,6828,0307,6267,8647,0436,6395,7175,8105,9086,1725,5955,5725,6523,3243,3173,4653,3542,3532,5342,4032,0841,1209156686475005685200544000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
126
220
0
0
0
304
304
304
304
304
304
304
0
334
363
363
363
363
361
361
361
361
361
361
361
415
415
415
415
585
5854154154154153613613613613613613613633633633633340304304304304304304304000220126000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
233,243
0
0
0
0
50,416
50,416
50,416
50,416
50,416
50,416
50,416
50,416
50,416
50,416
50,416
50,416
50,416
50,416
50,41650,41650,41650,41650,41650,41650,41650,41650,41650,41650,41650,41650,41650,4160000233,24300000000000000000000000000
       Other Assets 
0
0
0
86
0
0
0
85
0
769
0
85
126
131
130
130
220
211
217
327
304
304
304
304
304
304
304
334
427
424
394
363
363
361
361
361
0
361
0
0
0
0
0
0
0
0000000361036136136136336339442442733430430430430430430430432721721122013013013112685076908500086000
> Total Liabilities 
0
0
0
4,419
0
2,978
3,685
8,888
8,866
12,740
14,474
13,720
11,545
10,396
12,769
15,174
14,186
17,163
16,748
18,933
71,038
22,932
22,966
26,808
22,631
22,396
23,367
23,262
20,543
21,808
24,175
29,464
21,388
13,974
15,503
16,947
16,215
16,900
17,322
22,171
22,600
114,110
114,083
118,643
116,284
116,284118,643114,083114,11022,60022,17117,32216,90016,21516,94715,50313,97421,38829,46424,17521,80820,54323,26223,36722,39622,63126,80822,96622,93271,03818,93316,74817,16314,18615,17412,76910,39611,54513,72014,47412,7408,8668,8883,6852,97804,419000
   > Total Current Liabilities 
0
0
0
4,419
0
2,978
3,685
6,101
5,875
9,544
11,012
9,922
7,657
5,962
8,226
9,754
8,578
11,281
10,681
13,082
60,710
13,260
14,012
17,510
13,252
12,947
13,847
14,018
11,125
11,847
14,223
20,026
11,911
11,924
13,600
11,481
10,755
11,153
11,710
13,576
14,124
100,530
100,987
100,838
99,246
99,246100,838100,987100,53014,12413,57611,71011,15310,75511,48113,60011,92411,91120,02614,22311,84711,12514,01813,84712,94713,25217,51014,01213,26060,71013,08210,68111,2818,5789,7548,2265,9627,6579,92211,0129,5445,8756,1013,6852,97804,419000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
4,719
6,768
0
0
386
392
395
455
0
0
332
47,535
749
760
1,094
759
759
882
443
441
571
577
570
573
577
581
548
551
553
555
672
672
687
694
1,026
1,033
1,0331,0266946876726725555535515485815775735705775714414438827597591,09476074947,53533200455395392386006,7684,719000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
386
392
395
455
841
0
358
47,119
329
334
652
324
321
441
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000044132132465233432947,11935808414553953923860000000000000
       Accounts payable 
0
0
0
1,584
0
649
861
1,719
994
2,625
2,832
4,035
2,641
954
1,361
1,092
1,182
2,015
515
1,979
829
156
0
142
760
1,442
1,020
2,184
370
317
215
2,003
501
337
1,519
929
1,136
1,352
1,479
1,679
2,837
1,435
1,416
2,658
2,391
2,3912,6581,4161,4352,8371,6791,4791,3521,1369291,5193375012,0032153173702,1841,0201,44276014201568291,9795152,0151,1821,0921,3619542,6414,0352,8322,6259941,71986164901,584000
       Other Current Liabilities 
0
0
0
2,835
0
2,329
2,824
4,337
3,728
6,919
8,180
5,366
4,888
4,667
6,825
8,307
7,355
8,798
10,124
20,840
8,800
8,414
8,551
11,797
11,733
9,339
10,734
11,085
9,734
10,611
13,308
16,736
10,571
10,585
10,976
9,417
8,653
8,818
9,338
11,087
10,541
11,895
12,899
12,098
11,146
11,14612,09812,89911,89510,54111,0879,3388,8188,6539,41710,97610,58510,57116,73613,30810,6119,73411,08510,7349,33911,73311,7978,5518,4148,80020,84010,1248,7987,3558,3076,8254,6674,8885,3668,1806,9193,7284,3372,8242,32902,835000
   > Long-term Liabilities 
0
0
0
0
0
0
3,300
2,787
2,991
3,196
3,462
3,798
3,888
4,434
4,543
5,420
5,608
5,882
6,067
5,851
10,328
9,672
8,954
9,298
9,379
9,449
9,520
9,244
9,418
9,961
9,952
9,438
9,477
2,050
1,903
5,466
5,460
5,747
5,612
8,595
8,476
13,580
13,096
17,805
17,038
17,03817,80513,09613,5808,4768,5955,6125,7475,4605,4661,9032,0509,4779,4389,9529,9619,4189,2449,5209,4499,3799,2988,9549,67210,3285,8516,0675,8825,6085,4204,5434,4343,8883,7983,4623,1962,9912,7873,300000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
602
197
1,891
1,815
1,764
1,813
1,713
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000001,7131,8131,7641,8151,891197602000000000000000000
       Other Liabilities 
0
0
0
2,426
0
0
0
2,782
0
3,264
0
3,738
3,888
4,223
4,284
5,160
5,414
5,362
5,657
6,102
8,437
7,857
7,190
7,485
7,666
7,847
8,029
7,464
7,712
7,835
7,960
7,098
7,281
0
0
3,213
0
3,771
0
0
0
0
0
0
0
00000003,77103,213007,2817,0987,9607,8357,7127,4648,0297,8477,6667,4857,1907,8578,4376,1025,6575,3625,4145,1604,2844,2233,8883,73803,26402,7820002,426000
> Total Stockholder Equity
0
0
0
23,467
23,467
29,004
48,152
71,043
64,679
90,542
146,209
142,380
133,054
120,892
112,672
116,839
105,828
95,393
191,976
177,623
241,854
273,290
292,383
272,442
265,601
250,862
233,243
215,478
207,416
189,282
179,221
231,979
214,131
202,812
190,054
168,991
152,935
139,328
125,664
160,643
144,681
123,425
130,165
112,270
94,798
94,798112,270130,165123,425144,681160,643125,664139,328152,935168,991190,054202,812214,131231,979179,221189,282207,416215,478233,243250,862265,601272,442292,383273,290241,854177,623191,97695,393105,828116,839112,672120,892133,054142,380146,20990,54264,67971,04348,15229,00423,46723,467000
   Common Stock
0
0
0
854
0
855
856
928
928
988
1,126
1,135
1,139
1,142
1,143
1,147
1,147
1,149
1,351
1,351
1,361
1,436
1,436
1,437
1,437
1,438
1,539
1,538
1,539
1,539
1,589
1,794
1,795
1,796
1,797
1,797
1,797
1,800
1,802
2,089
2,093
2,212
2,218
2,226
2,230
2,2302,2262,2182,2122,0932,0891,8021,8001,7971,7971,7971,7961,7951,7941,5891,5391,5391,5381,5391,4381,4371,4371,4361,4361,3611,3511,3511,1491,1471,1471,1431,1421,1391,1351,1269889289288568550854000
   Retained Earnings Total Equity000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
23,467
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-4,896
0
0
0
0
0
0
0
0
49
72
10
2
-6
5
-51
-35
-35
-24
-5
-1
-1-5-24-35-35-515-6210724900000000-4,896000000000000000000023,4670000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
302,985
315,232
298,259
346,024
346,479
346,526
346,568
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000346,568346,526346,479346,024298,259315,232302,985000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
83,068
0
83,077
83,112
110,496
110,453
123,379
187,995
188,166
188,191
188,207
188,215
188,299
188,357
188,407
298,077
298,149
298,259
346,024
346,479
346,526
346,568
346,634
346,742
346,790
354,651
354,814
359,297
431,127
431,129
431,136
431,179
431,199
431,241
433,589
434,345
474,802
475,181
475,856
476,908
478,288
478,781
478,781478,288476,908475,856475,181474,802434,345433,589431,241431,199431,179431,136431,129431,127359,297354,814354,651346,790346,742346,634346,568346,526346,479346,024298,259298,149298,077188,407188,357188,299188,215188,207188,191188,166187,995123,379110,453110,49683,11283,077083,068000



5.3. Balance Sheets

Currency in CHF. All numbers in thousands.




5.4. Cash Flows

Currency in CHF. All numbers in thousands.




5.5. Income Statements

Currency in CHF. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in CHF. All numbers in thousands.

Gross Profit (+$)
totalRevenue27,309
Cost of Revenue-0
Gross Profit27,30927,309
 
Operating Income (+$)
Gross Profit27,309
Operating Expense-79,687
Operating Income-52,378-52,378
 
Operating Expense (+$)
Research Development62,570
Selling General Administrative11,434
Selling And Marketing Expenses0
Operating Expense79,68774,004
 
Net Interest Income (+$)
Interest Income3,196
Interest Expense-133
Other Finance Cost-0
Net Interest Income3,063
 
Pretax Income (+$)
Operating Income-52,378
Net Interest Income3,063
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-50,913-53,843
EBIT - interestExpense = -50,913
-50,913
-50,783
Interest Expense133
Earnings Before Interest and Taxes (EBIT)-50,780-50,780
Earnings Before Interest and Taxes (EBITDA)-48,618
 
After tax Income (+$)
Income Before Tax-50,913
Tax Provision-3
Net Income From Continuing Ops-50,916-50,916
Net Income-50,916
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses79,687
Total Other Income/Expenses Net1,465-3,063
 

Technical Analysis of AC Immune Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of AC Immune Ltd. The general trend of AC Immune Ltd is BEARISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine AC Immune Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-28.6%) Bearish trend (28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. AC Immune Ltd Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of AC Immune Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2.2 < 2.2299 < 2.25.

The bearish price targets are: 1.8 > 1.79 > 1.78.

Know someone who trades $ACIU? Share this with them.👇

AC Immune Ltd Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of AC Immune Ltd. The current mas is .

The long score for the Moving Averages is 5/14.
The longshort score for the Moving Averages is -4/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

AC Immune Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of AC Immune Ltd. The current macd is 0.07164956.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the AC Immune Ltd price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for AC Immune Ltd. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the AC Immune Ltd price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
AC Immune Ltd Daily Moving Average Convergence/Divergence (MACD) ChartAC Immune Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of AC Immune Ltd. The current adx is 27.18.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy AC Immune Ltd shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
AC Immune Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of AC Immune Ltd. The current sar is 1.83.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
AC Immune Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of AC Immune Ltd. The current rsi is 51.74. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending down: The RSI is trending down. -1
AC Immune Ltd Daily Relative Strength Index (RSI) ChartAC Immune Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of AC Immune Ltd. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the AC Immune Ltd price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
AC Immune Ltd Daily Stochastic Oscillator ChartAC Immune Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of AC Immune Ltd. The current cci is 24.71.

AC Immune Ltd Daily Commodity Channel Index (CCI) ChartAC Immune Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of AC Immune Ltd. The current cmo is -3.21330287.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
AC Immune Ltd Daily Chande Momentum Oscillator (CMO) ChartAC Immune Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of AC Immune Ltd. The current willr is -55.54849976.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that AC Immune Ltd is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
AC Immune Ltd Daily Williams %R ChartAC Immune Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of AC Immune Ltd.

AC Immune Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of AC Immune Ltd. The current atr is 0.13002981.

AC Immune Ltd Daily Average True Range (ATR) ChartAC Immune Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of AC Immune Ltd. The current obv is 74,784,277.

AC Immune Ltd Daily On-Balance Volume (OBV) ChartAC Immune Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of AC Immune Ltd. The current mfi is 64.65.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
AC Immune Ltd Daily Money Flow Index (MFI) ChartAC Immune Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for AC Immune Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-31DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-02-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-13RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-02-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-02-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-10WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-24RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-04BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-23RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-04-24CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-04-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-06-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

AC Immune Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of AC Immune Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.742
Ma 20Greater thanMa 501.853
Ma 50Greater thanMa 1001.710
Ma 100Greater thanMa 2002.029
OpenGreater thanClose1.960
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of AC Immune Ltd with someone you think should read this too:
  • Are you bullish or bearish on AC Immune Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about AC Immune Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about AC Immune Ltd

I send you an email if I find something interesting about AC Immune Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about AC Immune Ltd.

Receive notifications about AC Immune Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.